TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
AMGN

Amgen Inc

Healthcare · Drug Manufacturers - General

410.90$ +1.5% vs. previous close Closing price · As of: 7. Aug 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Amgen Inc (AMGN). It shows which part of the business is growing — and which one is holding it back.

Revenue by region

Revenue by region — AMGN
Segment 2020 2021 2022 2023 2024 2025
US $18.50B 72.8% $18.19B 70.0% · -1.6% $18.60B 70.6% · +2.2% $19.81B 70.3% · +6.5% $23.86B 71.4% · +20.5% $26.42B 71.9% · +10.7%
ROW [Member] $6.93B 27.2% $7.79B 30.0% · +12.4% $7.73B 29.4% · -0.7% $8.38B 29.7% · +8.5% $9.56B 28.6% · +14.0% $10.33B 28.1% · +8.1%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?